摘要
骨质疏松症是一种以骨量减少、骨组织细微结构受损,导致脆性骨折为特征的一种常见疾病。随着人类寿命延长和老年人口的增加,骨质疏松症患病率持续增高,且所致的疼痛和骨折严重影响患者的生活质量,故骨质疏松症的治疗非常重要。目前抗骨质疏松症药物的疗效和安全性比较明确,是防治骨质疏松症的主要手段,但临床上发现单药治疗作用有限,基于不同的作用机制,有学者提出抗骨质疏松症药物的联合治疗。本文针对抗骨质疏松症药物中的两类即抗骨吸收和促骨形成药物之间的联合应用进展做一综述。
Osteoporosis is a common disease characterized by bone loss and skeletal microarchitecture damage,leading to brittle fractures. With the prolongation of human life and the increase in the elderly population,the prevalence of osteoporosis continues to increase. The pain and fractures seriously affect the quality of life of the patients. Therefore the treatment of osteoporosis is very important. At present,drugs are the main means of prevention and treatment for osteoporosis,with clear efficacy and safety.However,the role of monotherapy is limited. Based on different mechanisms of action,some scholars suggest the combination use of anabolic and antiresorptive agents. This paper summarizes the progress of the combination therapy of anabolic agents and antiresorptive agents.
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2018年第3期399-405,共7页
Chinese Journal of Osteoporosis
关键词
骨质疏松症
促进骨形成
抑制骨吸收
联合治疗
Osteoporosis
Anabolic agents
Antiresorptive agents
Combination therapy